BD Gains Access to University College London Patient Samples for Assay Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Becton Dickinson and UCL Business, a subsidiary of University College London, announced this week an agreement that could lead to biomarker assays for ovarian and breast cancers.

The deal gives BD access to UCL's biobanks containing more than 200,000 human patient samples collected in prospective screening clinical trials for the detection and management of epithelial ovarian cancer. BD will use the samples to develop and validate biomarker assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.